TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: PK/PD of EA-230 During Endotoxemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 to 35 years inclusive~2. For part 2 only male~3. Subjects and their partners use a reliable way of contraception~4. BMI between 18 and 30 kg/m², with a lower limit of body weight of 50 kg~5. Healthy as determined by medical history, physical examination, vital signs, ECG, and clinical laboratory parameters~Exclusion Criteria:~1. Unwillingness to abstain from any medication, recreational drugs or anti-oxidant vitamin supplements during the course of the study and within 7 days prior to study Day 1.~2. Unwillingness to abstain from nicotine, or alcohol or within 1 day prior to study Day 1~3. Previous participation in a trial where LPS was administered~4. Surgery or trauma with significant blood loss or blood donation within 3 months prior to study Day 1~5. History, signs or symptoms of cardiovascular disease, in particular:~   * History of frequent vaso-vagal collapse or of orthostatic hypotension~  * Resting pulse rate ≤45 or ≥100 beats / min~  * Hypertension (RR systolic \>160 or RR diastolic \>90)~  * Hypotension (RR systolic \<100 or RR diastolic \<50)~  * conduction abnormalities on the ECG~6. Renal impairment: plasma creatinine \>120 µmol/L~7. Liver function tests (alkaline phosphatase, AST, ALT and/or γ-GT) above 2x the upper limit of normal.~8. History of asthma~9. Atopic constitution~10. CRP above 2x the upper limit of normal, or clinically significant acute illness, including infections, within 2 weeks before administration of the study drug.~11. Treatment with investigational drugs or participation in any other clinical trial within 30 days prior to study drug administration.~12. Known or suspected of not being able to comply with the trial protocol.~13. Known hypersensitivity to any excipients of the drug formulations used.~14. Inability to personally provide written informed consent (e.g. for linguistic or mental reasons) and/or take part in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- EA-230 (30mg/kg) (Type: ACTIVE_COMPARATOR): Subjects will receive EA-230, 30 mg/kg
- EA-230 (90mg/kg) (Type: ACTIVE_COMPARATOR): Subjects will receive EA-230, 90 mg/kg
- EA-230 (180mg/kg) (Type: ACTIVE_COMPARATOR): Subjects will receive EA-230, 180 mg/kg
- Placebo (Type: PLACEBO_COMPARATOR): subjects receive placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: REVITIVE for the Treatment of Patients With Venous Insufficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to understand the study and provide meaningful written informed consent for the study.~* Willing, able, and committed to participate in the procedures for the full length of the study.~* All ethnic groups, male or female above the age of 18 years.~* Diagnosis of chronic venous insufficiency (C2-C5 CEAP classified)~* Be of non-childbearing potential; or using adequate contraception and have a negative urine pregnancy test result within 24 hours if appropriate before using the device.~* Blood pressure currently under moderate control (\<160/100mmHg)~* No current foot ulceration.~Exclusion Criteria:~* Has insufficient ability to understand the subject information sheet, consent form and verbal instruction.~* Has an unstable condition (eg psychiatric disorder, a recent history of substance abuse or otherwise thought to be unreliable or incapable of complying wight he requirements of the clinical investigational plan (CIP).~* Has any metal implants.~* Pregnant.~* Has a cardiac pacemaker, AICD or other implanted electrical device.~* Has an existing DVT.~* Has an acute medical condition other than chronic venous insufficiency.~* Has recent lower limb injury or lower back pain.~* Has current foot ulceration or other skin ulcers.~* Has cardiovascular disease.~* Has foot deformities.~* Has any disorder that, in the opinion of the investigator, might interfere with the conduct of the study.~* Has an ABPI \< 0.8.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- REVITIVE IX: actual device (Type: ACTIVE_COMPARATOR): Trial participants will receive the true Revitive IX device
- REVITIVE IX: sham device (Type: SHAM_COMPARATOR): Trial participants will receive a sham device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Assess How Well Certolizumab Pegol Works in Patients With Moderate to Severe Plaque Psoriasis as Part of Routine Clinical Practice

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient is ≥18 years of age at observational point 1~* The patient must have a clinical diagnosis of moderate to severe Plaque psoriasis according to the diagnostic criteria used by the physician in routine clinical practice~* The patient has an available PASI assessment prior to the first certolizumab pegol dose according to the standard of care~* The patient must be newly prescribed with certolizumab pegol~* If a patient is participating in an ongoing investigational study, then he/she will not be able to take part in this study~Exclusion Criteria:~Not applicable

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Certolizumab pegol (Type: None): Plaque psoriasis patients who have been newly prescribed certolizumab pegol (CZP).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Endothelial Function in a Sample Group of Patients From the ICARE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diabetic patients aged 55 and above~Exclusion Criteria:~* Patient who takes antioxidant treatment will be asked to stop, or cannot be included in the study.~* Patients who had a cardiovascular disease (CVD) incident (myocardial infarction \[MI\], stroke, transient ischemic attack \[TIA\]), unstable angina pectoris, uncontrolled hypertension (HTN), will have to wait a month after stabilization to be included in the study.~* Allergy to vitamin E.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Psilocybin Cancer Anxiety Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: EARLY_PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 18-76~* Current or historical diagnosis of cancer~* Projected life expectancy of at least one year~* DSM-IV diagnoses: Acute Stress Disorder, Generalized Anxiety Disorder, Anxiety Disorder due to cancer, Adjustment Disorder with anxious features~* Any stage of cancer diagnosis~Exclusion Criteria:~* Epilepsy~* Renal disease~* Diabetes~* Abnormal liver function~* Severe cardiovascular disease~* Malignant Hypertension~* Baseline blood pressure must be less than or equal to 140/90~* Personal history or immediate family members with schizophrenia, bipolar affective disorder, delusional disorder, schizoaffective disorder or other psychotic spectrum illness~* Current substance use disorder~* Medication contraindications: anti-seizures medications, insulin, oral hypoglycemics, clonidine, aldomet, cardiovascular medications, anti-psychotics (first and second generation), anti-depressants and mood stabilizers

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 76 Years
- Healthy Volunteers: f

Study Arms:
- Psilocybin (Type: EXPERIMENTAL): Drug intervention
- Niacin (Type: ACTIVE_COMPARATOR): Active control

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients, 18-80 years of age;~* rheumatoid arthritis after inadequate response to \>=1 DMARD treatment;~* active disease;~* DMARDs other than methotrexate withdrawn for at least 4 weeks prior to start of study treatment.~Exclusion Criteria:~* autoimmune disease other than rheumatoid arthritis;~* bone/joint surgery within 8 weeks prior to screening, or joint surgery planned within 24 weeks of MabThera infusion;~* concurrent treatment with any DMARD or antiTNF-alfa;~* intra-articular or parenteral corticosteroids within 4 weeks prior to screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- MabThera/Rituxan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of the Combination of Two FDA Approved Oral Medications, Nebivolol and Valsartan for Treatment of Stage 1 or 2 Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients of age 18 years or above~* Patients diagnosed with stage 1 or stage 2 essential hypertension~* Normal physical examination findings, electrocardiogram (ECG) results and chest x-ray; or abnormal findings judged by the Investigator to be not clinically significant~Exclusion Criteria:~* Secondary hypertension or severe hypertension~* Clinically significant cardiovascular disease or heart failure~* Clinical significant respiratory disease that would prohibit the use of a beta blocker~* A medical contraindication to discontinuing a current antihypertensive therapy~* History of Type 1 diabetes mellitus~* History of Severe Mental Illness except mild depression

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nebivolol and Valsartan Fixed Dose Combination 1 (Type: EXPERIMENTAL): Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg
- Nebivolol and Valsartan Fixed Dose Combination 2 (Type: EXPERIMENTAL): Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg
- Nebivolol and Valsartan Fixed Dose Combination 3 (Type: EXPERIMENTAL): Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg
- Nebivolol Low Dose (Type: EXPERIMENTAL): Nebivolol Monotherapy 5 mg
- Nebivolol High Dose (Type: EXPERIMENTAL): Nebivolol Monotherapy 20 mg
- Valsartan Low Dose (Type: EXPERIMENTAL): Valsartan Monotherapy 80 mg
- Valsartan High Dose (Type: EXPERIMENTAL): Valsartan Monotherapy 160 mg
- Placebo (Type: PLACEBO_COMPARATOR): Dose Matched placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Behavioral Intervention for Depression and Chronic Pain in Primary Care

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 50 years~* PHQ-9 greater than or equal to 10~* Non-cancer related chronic pain, defined as pain during most days over the past 3 months by patient report~* Capacity to consent~Exclusion Criteria:~* DSM-5 Axis 1 other than depression and anxiety disorders~* Montreal Cognitive Assessment (MoCA) \< 24~* Active suicidal ideation, i.e. MADRS Suicide Item greater than or equal to 4~* Severe or life-threatening medical illness.~* Patients on psychotropics, opioids or benzodiazepines will be included if they do not meet DSM-5 criteria for opioid, anxiolytics or other substance abuse disorders

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Relief (Type: EXPERIMENTAL): Relief relies on a neurobiological model to simplify its behavioral targets and uses mobile technology to augment its interventions. Relief was co-developed with our primary care partners with the goal to be usable by non-physician clinicians of primary care offices eligible to provide billable services.
- Referral (Type: NO_INTERVENTION): Referral for mental health based on clinical indication.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Safety, Immunogenicity and LDLc -Lowering Activity of 2 PCSK9 Targeting AFFITOPE Vaccines in Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Subjects ≥ 18 years of age at time of study entry.~2. Fasting LDLc at screening.~3. Fasting triglycerides at screening.~4. Body weight \> 50 kg and a body mass index (BMI) between 19 and 35.~Exclusion Criteria:~1. Treatment/change in treatment with medications known to influence HDLc, LDLc and total cholesterol concentrations~2. Planned life-style changes during the study period like increasing aerobic exercise activity, attempting to lose body weight or changing the smoking status.~3. History of autoimmune diseases.~4. History of malignancy~5. Active or passive vaccination~6. Blood donation~7. History of severe hypersensitivity reactions and anaphylaxis.~8. History of allergic bronchial asthma.~9. Acquired or hereditary immunodeficiency.~10. Prior and/or current treatment with immune modulating drugs:~11. Subject has taken prescription lipid-regulating drugs~12. Treatment prior to screening with the following drugs: vitamin A derivatives and retinol derivatives for dermatologic treatment or any other drug known to influence cholesterol Levels~13. Infection with the human immunodeficiency Virus,Hepatitis B (HBsAg) or Hepatitis C.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- AFFITOPE® AT04A+adjuvant (Type: EXPERIMENTAL): 3 injections of 15µg AFFITOPE® AT04A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
- AFFITOPE® AT06A+adjuvant (Type: EXPERIMENTAL): 3 injections of 15µg AFFITOPE® AT06A+adjuvant once every 4 weeks and 1 boost immunization at a dose of 75μg, which will be applied one year after the 3rd immunization
- Adjuvant without active component (Type: PLACEBO_COMPARATOR): 3 injections of Placebo once every 4 weeks and 1 boost immunization which will be applied one year after the 3rd immunization

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Current treatment with once daily insulin glargine in vials with a daily dose equal to or above 65 U and equal to or below 100 U~* Current treatment with a stable dose of metformin plus/minus one additional oral antidiabetic drug (OAD) for at least 12 weeks~* Glycosylated haemoglobin (HbA1c) equal to or above 7.5%~Exclusion Criteria:~* Current treatment with insulin other than insulin glargine in vials~* Treatment with thiazolidinediones or glucagon-like peptide-1 (GLP-1) receptor agonists within 12 weeks~* Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty~* Suffer from cancer (except basal cell skin cancer and squamous-cell cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg followed by IGlar (Type: EXPERIMENTAL): None
- IGlar followed by IDeg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tight Glycemic Control During Angioplasty Revascularization Reduces Coronary Stent Restenosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* chest discomfort lasting at least 15 min within the last 24 h,~* new \>l mm ST-wave or dynamic T-wave changes in at least two contiguous ECG leads,~* troponin I levels above the 99th percentile 6-12 h after the onset of chest pain~* patients referred to the cardiac catheterization laboratory within 24 h of symptoms.~Exclusion Criteria:~* left ventricular ejection fraction less than 25%,~* hemorrhagic diatheses,~* contraindications or allergy to aspirin, thienopyridines, and history of anaphylaxis in response to iodinated contrast medium,~* serum creatinine level of more than 2.0 mg/dl (177 μmol/l),~* leukocyte count of less than 3500/mm3, platelet count of less than 100,000/mm3~* coexisting conditions that limited life expectancy to less than 24 months or that could affect a patient's compliance with the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- control (Type: NO_INTERVENTION): No hyperglycemia patient group
- Insulin 1 (Type: ACTIVE_COMPARATOR): Conventional insulin treatment
- Insulin (Type: EXPERIMENTAL): Intensive insulin treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Melatonin to Prevent Brain Injury in Unborn Growth Restricted Babies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Estimated fetal weight \<10th percentile in combination with abnormal fetoplacental Doppler studies.~* Singleton pregnancy.~* Live fetus.~* Gestational age: from 23+0 weeks until 34+0 weeks.~* Normal fetal anatomy on ultrasound.~* Confirmed gestational age.~* No indication for immediate delivery.~* Basic understanding of the English language.~* 18 years or older.~* Consent obtained.~Exclusion Criteria:~* Fetal demise.~* Multiple pregnancy.~* Known abnormal karyotype.~* Presence of any congenital abnormality.~* Unknown duration of pregnancy.~* IUGR attributable to non-placental factors.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Melatonin (Type: EXPERIMENTAL): Women with IUGR will take 4mg prolonged release melatonin oral tablets twice daily. Treatment will occur as soon as the diagnosis of intrauterine growth restriction is made and the patient has been enrolled to this study until birth. The overall duration of treatment will vary due to the nature of intrauterine growth restriction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete